Jade Biosciences (JBIO) Cash from Financing Activities (2021 - 2026)
Jade Biosciences (JBIO) posted Cash from Financing Activities of -$795000.0 for Q1 2026, down 100.47% on a QoQ basis from $170.2 million in Q4 2025, and down 13.57% year-over-year from -$919834.7 in Q1 2025.
Jade Biosciences (JBIO) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Jade Biosciences' Cash from Financing Activities history runs 6 years deep, the most recent figure standing at -$795000.0 for Q1 2026.
- Quarterly Cash from Financing Activities fell 13.57% year-over-year to -$795000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $360.7 million (up 93.84% YoY) and the FY2025 annual result came in at $360.8 million, up 1318.84% from the prior year.
- Cash from Financing Activities was -$795000.0 for Q1 2026 at Jade Biosciences, down from $170.2 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $191.3 million in Q2 2025 and bottomed at -$795000.0 in Q1 2026.
- A 5-year average of $45.7 million and a median of $463000.0 in 2023 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 473760.0% — and 2025, when it tumbled 248.62%.
- Jade Biosciences' Cash from Financing Activities stood at $357000.0 in 2022, then rose by 29.69% to $463000.0 in 2023, then surged by 19770.41% to $92.0 million in 2024, then soared by 84.96% to $170.2 million in 2025, then slumped by 100.47% to -$795000.0 in 2026.
- Business Quant data shows JBIO's Cash from Financing Activities at -$795000.0 in Q1 2026, $170.2 million in Q4 2025, and $191.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Jade Biosciences | 16.25 Mn | 16.25 Mn | - | -795,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -795,000.00 |
| Mar 31, 2026 | -795,000.00 |
| Dec 31, 2025 | 170.16 Mn |
| Dec 31, 2025 | 170.16 Mn |
| Jun 30, 2025 | 191.31 Mn |
| Jun 30, 2025 | 191.31 Mn |
| Mar 31, 2025 | -700,000.00 |
| Mar 31, 2025 | -700,000.00 |
| Dec 31, 2024 | 92.00 Mn |
| Dec 31, 2024 | 92.00 Mn |
| Sep 30, 2024 | 94.77 Mn |
| Sep 30, 2024 | 94.77 Mn |
| Mar 31, 2024 | 471,000.00 |
| Mar 31, 2024 | 471,000.00 |
| Dec 31, 2023 | 463,000.00 |
| Dec 31, 2023 | 463,000.00 |
| Sep 30, 2023 | 20,000.00 |
| Sep 30, 2023 | 20,000.00 |
| Jun 30, 2023 | 45.29 Mn |
| Jun 30, 2023 | 45.29 Mn |